Developments in STD/HIV interactions: The intertwining epidemics of HIV and HSV-2

Research output: Contribution to journalArticle

Abstract

Antiviral agents aimed at treating HSV-2 chronically infected individuals have proven to be effective in the prevention of symptomatic genital herpes and the reduction of viral shedding. These agents play a key role in current HIV prevention trials that will assess the role of suppression of HSV-2 infection on the risk for HIV acquisition and transmission. An added clinical benefit of treating HSV-2/HIV-coinfected individuals is the potential survival benefit, as suggested by earlier studies and by the recent findings that HSV-2/HIV dually infected individuals have higher viral loads [32]. The results of the current HSV-2 suppression trials may provide additional tools to fight the global spread of HIV infection. Treatment of HSV-2/HIV dually infected individuals may prove to be a low-cost intervention to improve clinical outcomes and delay the need for antiretroviral therapy.

Original languageEnglish (US)
Pages (from-to)415-425
Number of pages11
JournalInfectious Disease Clinics of North America
Volume19
Issue number2 SPEC. ISS.
DOIs
StatePublished - Jun 2005

Fingerprint

HIV-2
Human Herpesvirus 2
Sexually Transmitted Diseases
HIV
Virus Shedding
Herpes Genitalis
Viral Load
HIV Infections
Antiviral Agents
Costs and Cost Analysis
Infection

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Developments in STD/HIV interactions : The intertwining epidemics of HIV and HSV-2. / Reynolds, Steven James; Quinn, Thomas C.

In: Infectious Disease Clinics of North America, Vol. 19, No. 2 SPEC. ISS., 06.2005, p. 415-425.

Research output: Contribution to journalArticle

@article{d66117cb931e42c0956d5e94ff243f34,
title = "Developments in STD/HIV interactions: The intertwining epidemics of HIV and HSV-2",
abstract = "Antiviral agents aimed at treating HSV-2 chronically infected individuals have proven to be effective in the prevention of symptomatic genital herpes and the reduction of viral shedding. These agents play a key role in current HIV prevention trials that will assess the role of suppression of HSV-2 infection on the risk for HIV acquisition and transmission. An added clinical benefit of treating HSV-2/HIV-coinfected individuals is the potential survival benefit, as suggested by earlier studies and by the recent findings that HSV-2/HIV dually infected individuals have higher viral loads [32]. The results of the current HSV-2 suppression trials may provide additional tools to fight the global spread of HIV infection. Treatment of HSV-2/HIV dually infected individuals may prove to be a low-cost intervention to improve clinical outcomes and delay the need for antiretroviral therapy.",
author = "Reynolds, {Steven James} and Quinn, {Thomas C}",
year = "2005",
month = "6",
doi = "10.1016/j.idc.2005.04.005",
language = "English (US)",
volume = "19",
pages = "415--425",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "2 SPEC. ISS.",

}

TY - JOUR

T1 - Developments in STD/HIV interactions

T2 - The intertwining epidemics of HIV and HSV-2

AU - Reynolds, Steven James

AU - Quinn, Thomas C

PY - 2005/6

Y1 - 2005/6

N2 - Antiviral agents aimed at treating HSV-2 chronically infected individuals have proven to be effective in the prevention of symptomatic genital herpes and the reduction of viral shedding. These agents play a key role in current HIV prevention trials that will assess the role of suppression of HSV-2 infection on the risk for HIV acquisition and transmission. An added clinical benefit of treating HSV-2/HIV-coinfected individuals is the potential survival benefit, as suggested by earlier studies and by the recent findings that HSV-2/HIV dually infected individuals have higher viral loads [32]. The results of the current HSV-2 suppression trials may provide additional tools to fight the global spread of HIV infection. Treatment of HSV-2/HIV dually infected individuals may prove to be a low-cost intervention to improve clinical outcomes and delay the need for antiretroviral therapy.

AB - Antiviral agents aimed at treating HSV-2 chronically infected individuals have proven to be effective in the prevention of symptomatic genital herpes and the reduction of viral shedding. These agents play a key role in current HIV prevention trials that will assess the role of suppression of HSV-2 infection on the risk for HIV acquisition and transmission. An added clinical benefit of treating HSV-2/HIV-coinfected individuals is the potential survival benefit, as suggested by earlier studies and by the recent findings that HSV-2/HIV dually infected individuals have higher viral loads [32]. The results of the current HSV-2 suppression trials may provide additional tools to fight the global spread of HIV infection. Treatment of HSV-2/HIV dually infected individuals may prove to be a low-cost intervention to improve clinical outcomes and delay the need for antiretroviral therapy.

UR - http://www.scopus.com/inward/record.url?scp=20444457566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444457566&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2005.04.005

DO - 10.1016/j.idc.2005.04.005

M3 - Article

C2 - 15963880

AN - SCOPUS:20444457566

VL - 19

SP - 415

EP - 425

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 2 SPEC. ISS.

ER -